Meet SciSparc Ltd. (NASDAQ: SPRC) the Cannabis biotech disruptor with potential pipeline revenues of about $490M and they already have an approved drug in Canada! Float approx. 2.3M shares.

We Love This Stock!

SciSparc Ltd. (NASDAQ: SPRC) already has a fully approved commercial product CannAmide, approved by Health Canada. CannAmide™ is recommended for use as an anti-inflammatory to help relieve chronic pain while the tablets will be marketed to pharmacies and other retail outlets across Canada.

This is incredible news as until now, op-i-oids are pretty much the only option for many people. But we all know the devastating effects op-i-oid abuse is wreaking on the world.

Cann-a-bis buds are covered in sticky, shining dots of resin, and in this resin are hundreds of therapeutic compounds that contribute to the effects and benefits of cann-a-bis.

In those compounds lies the secret to incredible potential.

Those hidden compounds the plant produces work together to create unique effects and benefits known as “the entourage effect.”

They can produce a synergy in the body to reduce inflammation and allow other dr-ugs to do their job.

THAT is a MASSIVE differentiator which makes SciSparc Ltd. (NASDAQ: SPRC) so unique and so compelling.

Leveraging the “entourage effect” the company has three powerhouse cann-a-bis-based dr-ugs in late development to help treat Tourette Syndrome (TS), Obstructive Sleep Apnea (OSA), and Autism Spectrum Disorder (ASD).

I WILL have more on this one soon.


Please visit the Full Report Here

Patent news issued today!

Privacy policy and disclaimer